Defining Differentiated Thyroid Cancer (DTC) and Radioactive Iodine-Refractory Differentiated Thyroid Cancer (DAI-R-DTC)

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

An updated analysis on larotrectinib showed compelling data in TRK fusion thyroid carcinoma.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

A small papillary thyroid cancer study demonstrates favorable outcomes and highlights the role of American Thyroid Association risk stratification.